Summary
Global Markets Direct’s, ‘Ewing Sarcoma - Pipeline Review, H1 2016’, provides an overview of the Ewing Sarcoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Ewing Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Ewing Sarcoma
- The report reviews pipeline therapeutics for Ewing Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Ewing Sarcoma therapeutics and enlists all their major and minor projects
- The report assesses Ewing Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Ewing Sarcoma
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Astellas Pharma Inc.
Cebiotex, S.L.
Celgene Corporation
EntreChem, S.L.
Exelixis, Inc.
Gradalis Inc.
Ipsen S.A.
Kolltan Pharmaceuticals, Inc.
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
NanoSmart Pharmaceuticals, Inc.
Nanovalent Pharmaceuticals Inc.
NantKwest, Inc.
Novartis AG
Oncomatryx Biopharma, S.L.
Recombio S.L
Shionogi & Co., Ltd.
Sigma-Tau S.p.A.
Tesaro, Inc.
Tokalas, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Ewing Sarcoma Overview 10
Therapeutics Development 11
Pipeline Products for Ewing Sarcoma - Overview 11
Pipeline Products for Ewing Sarcoma - Comparative Analysis 12
Ewing Sarcoma - Therapeutics under Development by Companies 13
Ewing Sarcoma - Therapeutics under Investigation by Universities/Institutes 15
Ewing Sarcoma - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Ewing Sarcoma - Products under Development by Companies 18
Ewing Sarcoma - Products under Investigation by Universities/Institutes 20
Ewing Sarcoma - Companies Involved in Therapeutics Development 21
Astellas Pharma Inc. 21
Cebiotex, S.L. 22
Celgene Corporation 23
EntreChem, S.L. 24
Exelixis, Inc. 25
Gradalis Inc. 26
Ipsen S.A. 27
Kolltan Pharmaceuticals, Inc. 28
Merck & Co., Inc. 29
Merrimack Pharmaceuticals, Inc. 30
NanoSmart Pharmaceuticals, Inc. 31
Nanovalent Pharmaceuticals Inc. 32
NantKwest, Inc. 33
Novartis AG 34
Oncomatryx Biopharma, S.L. 35
Recombio S.L 36
Shionogi & Co., Ltd. 37
Sigma-Tau S.p.A. 38
Tesaro, Inc. 39
Tokalas, Inc. 40
Ewing Sarcoma - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
3BP-227 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
cabozantinib s-malate - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
CEB-01 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Cellular Immunotherapy for Oncology - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
celyvir - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
EC-8042 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
EC-8105 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
everolimus - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
gemogenovatucel-T - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
haNK Program - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
irinotecan hydrochloride - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
KIT-SG3227 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
linsitinib - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Monoclonal Antibody Conjugate 1 for Ewing Sarcoma - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
niraparib - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
NV-101 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
OMTX-503 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
OMTX-703 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
paclitaxel albumin bound - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
pazopanib hydrochloride - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
pembrolizumab - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
racotumomab - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
RNAi Gene Therapy to Inhibit EWS and FLI1 for Ewing Sarcoma - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
roneparstat - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
S-588410 - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
Small Molecules for Ewing Sarcoma - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
SP-2509 - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
SP-2528 - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
SP-2577 - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
TK-216 - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
YK-4279 - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
Ewing Sarcoma - Recent Pipeline Updates 127
Ewing Sarcoma - Dormant Projects 189
Ewing Sarcoma - Discontinued Products 190
Ewing Sarcoma - Product Development Milestones 191
Featured News & Press Releases 191
Oct 09, 2015: Novel compound turns off mutant cancer gene in animals with leukemia 191
Jul 30, 2015: NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 191
Jun 04, 2015: Gradalis Announces Presentation of Data From a Pilot Study of Vigil Cancer Vaccine in Ewing’s Sarcoma 192
Feb 11, 2015: NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewing's Sarcoma 192
Nov 26, 2012: Possible New Treatment for a Childhood Cancer 193
Apr 16, 2012: EntreChem's Mithramycin Analog EC-8042 Shows Increased Potency And High Selectivity For Treatment Of Sarcoma 194
Apr 16, 2012: EntreChem's Mithramycin Shows Increased Potency And Higher Selectivity For Treatment Of Sarcoma 194
Appendix 195
Methodology 195
Coverage 195
Secondary Research 195
Primary Research 195
Expert Panel Validation 195
Contact Us 195
Disclaimer 196
List of Tables
Number of Products under Development for Ewing Sarcoma, H1 2016 11
Number of Products under Development for Ewing Sarcoma - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Development by Companies, H1 2016 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2016 20
Ewing Sarcoma - Pipeline by Astellas Pharma Inc., H1 2016 21
Ewing Sarcoma - Pipeline by Cebiotex, S.L., H1 2016 22
Ewing Sarcoma - Pipeline by Celgene Corporation, H1 2016 23
Ewing Sarcoma - Pipeline by EntreChem, S.L., H1 2016 24
Ewing Sarcoma - Pipeline by Exelixis, Inc., H1 2016 25
Ewing Sarcoma - Pipeline by Gradalis Inc., H1 2016 26
Ewing Sarcoma - Pipeline by Ipsen S.A., H1 2016 27
Ewing Sarcoma - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016 28
Ewing Sarcoma - Pipeline by Merck & Co., Inc., H1 2016 29
Ewing Sarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 30
Ewing Sarcoma - Pipeline by NanoSmart Pharmaceuticals, Inc., H1 2016 31
Ewing Sarcoma - Pipeline by Nanovalent Pharmaceuticals Inc., H1 2016 32
Ewing Sarcoma - Pipeline by NantKwest, Inc., H1 2016 33
Ewing Sarcoma - Pipeline by Novartis AG, H1 2016 34
Ewing Sarcoma - Pipeline by Oncomatryx Biopharma, S.L., H1 2016 35
Ewing Sarcoma - Pipeline by Recombio S.L, H1 2016 36
Ewing Sarcoma - Pipeline by Shionogi & Co., Ltd., H1 2016 37
Ewing Sarcoma - Pipeline by Sigma-Tau S.p.A., H1 2016 38
Ewing Sarcoma - Pipeline by Tesaro, Inc., H1 2016 39
Ewing Sarcoma - Pipeline by Tokalas, Inc., H1 2016 40
Assessment by Monotherapy Products, H1 2016 41
Number of Products by Stage and Target, H1 2016 43
Number of Products by Stage and Mechanism of Action, H1 2016 46
Number of Products by Stage and Route of Administration, H1 2016 48
Number of Products by Stage and Molecule Type, H1 2016 50
Ewing Sarcoma Therapeutics - Recent Pipeline Updates, H1 2016 127
Ewing Sarcoma - Dormant Projects, H1 2016 189
Ewing Sarcoma - Discontinued Products, H1 2016 190
List of Figures
Number of Products under Development for Ewing Sarcoma, H1 2016 11
Number of Products under Development for Ewing Sarcoma - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Products, H1 2016 17
Assessment by Monotherapy Products, H1 2016 41
Number of Products by Top 10 Targets, H1 2016 42
Number of Products by Stage and Top 10 Targets, H1 2016 42
Number of Products by Top 10 Mechanism of Actions, H1 2016 45
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 45
Number of Products by Routes of Administration, H1 2016 47
Number of Products by Stage and Routes of Administration, H1 2016 47
Number of Products by Molecule Types, H1 2016 49
Number of Products by Stage and Molecule Types, H1 2016 49
